No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CDNA CareDx
- 15.570
- +0.440+2.91%
Close May 22 16:00 ET
- 15.830
- +0.260+1.67%
Post 18:59 ET
810.94MMarket Cap-4552P/E (TTM)
15.700High14.780Low636.17KVolume14.970Open15.130Pre Close9.87MTurnover1.25%Turnover RatioLossP/E (Static)52.08MShares16.15052wk High3.17P/B790.61MFloat Cap4.80052wk Low--Dividend TTM50.78MShs Float99.830Historical High--Div YieldTTM6.08%Amplitude0.760Historical Low15.514Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
CareDx Is Maintained at Buy by Craig-Hallum
CareDx Is Maintained at Buy by Craig-Hallum
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Amgen (AMGN) and Orasure Technologies (OSUR)
Express News | CareDx, Inc. : Craig-Hallum Raises Target Price to $22 From $15
Landmark Study Shows CareDx's HeartCare Outperforms Dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes With Fewer Biopsies
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive
Express News | HC Wainwright & Co. Reiterates Neutral on CareDx
Balanced Outlook for CareDx: Strong Performance Amid Rising Competition
Comments
Investors may believe CareDx's strong revenue growth is not imminent, leading to a low P/S ratio. Expected future revenue decline could further decrease the P/S ratio, making a significant stock price rise unlikely.
Little Excitement Around CareDx, Inc's (NASDAQ:CDNA) Revenues As Shares Take 28% PoundingDespite a strong price move, CareDx's P/S ratio still trails the industry. The low P/S is due to the forecast for sliding revenue. Without significant change, drastic rise in the stock is unlikely.
$CareDx(CDNA.US$ 4.80 missed and ran 📈👀
$CareDx(CDNA.US$ Check out these highlights! ((. Reported revenue of $67.2 million, an increase of 7% over the second
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg